C-ITGTAeovian Pharmaceuticals
selective mTORC1 inhibition, CD38 inhibition, small molecules
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-ITGT
C-ITGTC-ITGTselective mTORC1 inhibition, CD38 inhibition, small molecules
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Aeovian Pharmaceuticals selective mTORC1 inhibition, CD38 inhibition, small molecules
Aeovian Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted and highly selective small molecules to restore cellular metabolic quality control. Its lead development candidate, AV078, is a first-in-class CNS-penetrant selective mTORC1 inhibitor for tuberous sclerosis complex refractory epilepsy. The company also describes a proprietary library of small molecules that inhibit either mTORC1 or CD38 for rare and age-related diseases.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Aeovian Pharmaceuticals — Translational · Bottom quartile. Derived deterministically from 3 extracted project(s). Most-advanced status: phase 1. Band: translational. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic